Abstract |
The avidity of many metastatic pheochromocytomas and neuroblastomas for metaiodobenzylguanidine ( MIBG) observed at diagnostic scintigraphy has led to attempts to treat these lesions with large doses of MIBG. We and others have achieved therapeutic responses with 131I-MIBG (usually partial) in about a third of malignant pheochromocytomas. A small but important subgroup of advanced, poor prognosis neuroblastomas which have been resistant to all other therapies have also shown responses including occasional long-term survival (> 5 years) and apparent complete responses to 131I-MIBG. Because the physical properties of 131I are suboptimal for the delivery of therapeutic radiation to bone marrow micrometastases, a frequent problem in neuroblastoma, we have performed preliminary studies in poor prognosis Stage III and VI neuroblastoma using 125I-MIBG which has more satisfactory emissions. This has led to prolonged tumor stabilization and survival (> 19 to > 52 months) in 5 of 10 patients. MIBG radiopharmaceutical treatment of neuroendocrine tumor patients must still be considered an experimental but nevertheless promising treatment modality.
|
Authors | B Shapiro, J C Sisson, B L Shulkin, M D Gross, S Zempel |
Journal | The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR)
(Q J Nucl Med)
Vol. 39
Issue 4 Suppl 1
Pg. 55-7
(Dec 1995)
ISSN: 1125-0135 [Print] Italy |
PMID | 9002750
(Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)
|
Chemical References |
- Iodine Radioisotopes
- Iodobenzenes
- Radiopharmaceuticals
- 3-Iodobenzylguanidine
|
Topics |
- 3-Iodobenzylguanidine
- Adrenal Gland Neoplasms
(diagnostic imaging, radiotherapy)
- Adult
- Bone Marrow Neoplasms
(radiotherapy, secondary)
- Child
- Humans
- Iodine Radioisotopes
(administration & dosage, chemistry, therapeutic use)
- Iodobenzenes
(administration & dosage, therapeutic use)
- Neoplasm Recurrence, Local
(radiotherapy)
- Neoplasm Staging
- Neoplasm, Residual
(radiotherapy)
- Neuroblastoma
(diagnostic imaging, radiotherapy, secondary)
- Pheochromocytoma
(diagnostic imaging, radiotherapy, secondary)
- Prognosis
- Radionuclide Imaging
- Radiopharmaceuticals
(administration & dosage, therapeutic use)
- Radiotherapy Dosage
- Remission Induction
- Survival Rate
|